{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T02:19:17Z","timestamp":1780366757178,"version":"3.54.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Japanese Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["Cancer Control-General-23EA1033"],"award-info":[{"award-number":["Cancer Control-General-23EA1033"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We aimed at estimating trends in 5-year net survival for myeloid and lymphoid malignancies, by age group and morphological subtype, using data on patients diagnosed during 2000\u20132014 and registered by 16 Japanese population-based cancer registries participating in the CONCORD-3 study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed data on adult patients (15\u201399\u00a0years) diagnosed with a myeloid or lymphoid malignancy during 2000\u20132014 and followed up to December 31, 2014. We estimated 5-year net survival by age group and morphological subtype with the Pohar Perme estimator, and age-standardized the estimates using International Cancer Survival Standard weights.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Significant improvements were observed in five-year net survival for myeloid malignancies among patients aged 15\u201344\u00a0years (from 57.3% in 2000\u20132004 to 72.3% in 2010\u20132014) and 45\u201354\u00a0years (from 41.9% to 61.3% over the same period). For lymphoid malignancies, 5-year net survival improved for all ages, but the improvement was less pronounced for older patients. Five-year net survival improved by 10% or more for myeloproliferative neoplasms, classic Hodgkin\u2019s lymphoma, and follicular lymphoma. Moderate improvement was observed for diffuse B-cell lymphoma and acute myeloid leukemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Five-year net survival for patients with hematological malignancies improved throughout 2000\u20132014 in Japan. The improvement was more pronounced in younger than older patients. Continuous and detailed monitoring of cancer survival trends is crucial for devising effective control strategies for hematological malignancies. [221\/250 words].<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyaf145","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T11:49:04Z","timestamp":1756986544000},"page":"i103-i115","source":"Crossref","is-referenced-by-count":2,"title":["Trends in survival for adult patients with hematopoietic malignancies in Japan, 2000\u201314 (CONCORD-3)"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5234-0507","authenticated-orcid":false,"given":"Isao","family":"Yoshida","sequence":"first","affiliation":[{"name":"Department of Hematologic Oncology, NHO Shikoku Cancer Center , Kou 160, Minamiumemoto-cho, Matsuyama, Ehime 791-0280 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7244-9526","authenticated-orcid":false,"given":"Veronica","family":"Di Carlo","sequence":"additional","affiliation":[{"name":"Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine , Keppel Street, London WC1E 7HT ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Matz","sequence":"additional","affiliation":[{"name":"Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine , Keppel Street, London WC1E 7HT ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention and Epidemiology, Center for Cancer Research, NHO Shikoku Cancer Center , Kou 160, Minamiumemoto-cho, Matsuyama, Ehime 791-0280 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7922-1871","authenticated-orcid":false,"given":"Norihiro","family":"Teramoto","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention and Epidemiology, Center for Cancer Research, NHO Shikoku Cancer Center , Kou 160, Minamiumemoto-cho, Matsuyama, Ehime 791-0280 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5200-9310","authenticated-orcid":false,"given":"Izumi","family":"Oki","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Saitama Prefectural University , 820 Sannomiya, Koshigaya, Saitama 343-8540 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Shibata","sequence":"additional","affiliation":[{"name":"Yamagata Prefectural Central Hospital , 1800 Oaza-Aoyanagi, Yamagata, Yamagata 990-2214 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9782-8637","authenticated-orcid":false,"given":"Kayo","family":"Nakata","sequence":"additional","affiliation":[{"name":"Cancer Control Center, Osaka International Cancer Institute , 3-1-69 Otemae, Chuo-ku, Osaka, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari Kajiwara","family":"Saito","sequence":"additional","affiliation":[{"name":"Cancer Control Center, Osaka International Cancer Institute , 3-1-69 Otemae, Chuo-ku, Osaka, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8199-3037","authenticated-orcid":false,"given":"Masashi","family":"Matsuzaka","sequence":"additional","affiliation":[{"name":"Hirosaki University Hospital , 53 Honcho, Hirosaki, Aomori 036-8563 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0712-2505","authenticated-orcid":false,"given":"Marisa","family":"Nishio","sequence":"additional","affiliation":[{"name":"Division of Prevention, National Cancer Center , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]},{"name":"Department of Medical Statistics , Faculty of Medicine, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi, Takatsuki, Osaka 569-8686,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0762-1147","authenticated-orcid":false,"given":"Isao","family":"Oze","sequence":"additional","affiliation":[{"name":"Division of Cancer Information and Control, Aichi Cancer Center Research Institute , 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6155-5283","authenticated-orcid":false,"given":"Kaname","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Cancer Prevention and Control Division, Kanagawa Cancer Center Research Institute , 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa 241-8515 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4626-0644","authenticated-orcid":false,"given":"Rina","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Hirosaki University Graduate School of Medicine , 5, Zaifucho, Hirosaki, Aomori 036-8562 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0331-3235","authenticated-orcid":false,"given":"Laureline","family":"Gatellier","sequence":"additional","affiliation":[{"name":"Division of International Health Policy Research, Institute for Cancer Control, National Cancer Center , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8023-4581","authenticated-orcid":false,"given":"Hidemi","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Cancer Information and Control, Aichi Cancer Center Research Institute , 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuharu","family":"Kaizaki","sequence":"additional","affiliation":[{"name":"Fukui Prefectural Hospital , 2-8-1 Yotsui, Fukui, Fukui, 910-8526 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Moki","sequence":"additional","affiliation":[{"name":"Gunma Health Foundation , 16-1 Horinoshita-machi, Maebashi, Gunma 371-0005 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuki","family":"Kurosawa","sequence":"additional","affiliation":[{"name":"Ibaraki Prefectural Office , 978-6, Kasahara-cho, Mito, Ibaraki 310-8555 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Nemoto","sequence":"additional","affiliation":[{"name":"Ibaraki Pharmaceutical Association Inspection Center , 978-47, Kasahara-cho, Mito, Ibaraki 310-0852 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0383-4911","authenticated-orcid":false,"given":"Hiroto","family":"Narimatsu","sequence":"additional","affiliation":[{"name":"Cancer Prevention and Control Division, Kanagawa Cancer Center Research Institute , 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa 241-8515 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiki","family":"Kanemura","sequence":"additional","affiliation":[{"name":"Miyagi Cancer Center Research Institute , 47-1 Nodayama, Medeshima-Shiote, Natori, Miyagi 981-1293 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Miyashiro","sequence":"additional","affiliation":[{"name":"Cancer Control Center, Osaka International Cancer Institute , 3-1-69 Otemae, Chuo-ku, Osaka, Osaka 541-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Mori","sequence":"additional","affiliation":[{"name":"Saga-ken Medical Centre Koseikan , 400 Nakabaru, Kasemachi, Saga, Saga 840-8571 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Fujita","sequence":"additional","affiliation":[{"name":"Tochigi Cancer Center , 4-9-13, Yohnan, Utsunomiya, Tochigi 320-0834 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-0865","authenticated-orcid":false,"given":"Hiromi","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Radiation Effects Research Foundation , 5-2 Hijiyama Park, Minami-ku, Hiroshima, Hiroshima 732-0815 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7311-1233","authenticated-orcid":false,"given":"Tomohiro","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Division of International Health Policy Research, Institute for Cancer Control, National Cancer Center , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel P","family":"Coleman","sequence":"additional","affiliation":[{"name":"Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine , Keppel Street, London WC1E 7HT ,","place":["United Kingdom"]},{"name":"Cancer Division, University College London Hospitals NHS Foundation Trust , 250 Euston Road, London NW1 2PG ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4871-3766","authenticated-orcid":false,"given":"Claudia","family":"Allemani","sequence":"additional","affiliation":[{"name":"Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine , Keppel Street, London WC1E 7HT ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"2026032004354109200_ref1","volume-title":"Pathology and genetics of tumours of haematopoietic and lymphoid tissues","author":"Jaffe","year":"2001","edition":"3rd"},{"key":"2026032004354109200_ref2","volume-title":"World Health Organization classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008","edition":"4th"},{"key":"2026032004354109200_ref3","volume-title":"International classification of diseases for oncology","author":"Percy","year":"1990","edition":"Second"},{"key":"2026032004354109200_ref4","volume-title":"International classification of diseases for oncology","author":"Fritz","year":"2000","edition":"Third"},{"key":"2026032004354109200_ref5","year":"2024"},{"key":"2026032004354109200_ref6","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet."},{"key":"2026032004354109200_ref7","first-page":"i","article-title":"Manual for coding and reporting haematological malignancies","volume":"96","author":"Group HW","year":"2010","journal-title":"Tumori."},{"key":"2026032004354109200_ref8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1541-0420.2011.01640.x","article-title":"On estimation in relative survival","volume":"68","author":"Pohar Perme","year":"2012","journal-title":"Biometrics."},{"key":"2026032004354109200_ref9","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/(SICI)1097-0142(19961101)78:9&lt;2004::AID-CNCR23&gt;3.0.CO;2-#","article-title":"An alternative approach to monitoring cancer patient survival","volume":"78","author":"Brenner","year":"1996","journal-title":"Cancer."},{"key":"2026032004354109200_ref10"},{"key":"2026032004354109200_ref11"},{"key":"2026032004354109200_ref12"},{"key":"2026032004354109200_ref13","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1186\/s12889-015-2534-3","article-title":"Multivariable flexible modelling for estimating complete, smoothed life tables for sub-national populations","volume":"15","author":"Rachet","year":"2015","journal-title":"BMC Public Health"},{"key":"2026032004354109200_ref14","article-title":"et\u00a0al","author":"Di Carlo"},{"key":"2026032004354109200_ref15","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1016\/j.ejca.2004.07.002","article-title":"Standard cancer patient population for age standardising survival ratios","volume":"40","author":"Corazziari","year":"2004","journal-title":"Eur J Cancer"},{"key":"2026032004354109200_ref16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/1536867X1401400107","article-title":"Net survival estimation with stns","volume":"14","author":"Clerc-Urm\u00e8s","year":"2014","journal-title":"Stata J"},{"key":"2026032004354109200_ref17","doi-asserted-by":"publisher","first-page":"768.e1","DOI":"10.1016\/j.jtct.2023.09.010","article-title":"Improved long-term net survival after allogeneic hematopoietic cell transplantation in patients with hematologic malignancies over two decades","volume":"29","author":"Ohbiki","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"2026032004354109200_ref18","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"IRIS investigators five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"2026032004354109200_ref19","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"2026032004354109200_ref20","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"2026032004354109200_ref21","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00277-018-3323-8","article-title":"Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL","volume":"97","author":"Hatta","year":"2018","journal-title":"Ann Hematol"},{"key":"2026032004354109200_ref22","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/00008469-200508000-00002","article-title":"International rules for multiple primary cancers","volume":"14","author":"Working Group R","year":"2005","journal-title":"Eur J Cancer Prev"},{"key":"2026032004354109200_ref23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"2026032004354109200_ref24","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1002\/cncr.30903","article-title":"A call for action: increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials","volume":"123","author":"Zeidan","year":"2017","journal-title":"Cancer."},{"key":"2026032004354109200_ref25","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the national LymphoCare study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026032004354109200_ref26","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"key":"2026032004354109200_ref27","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood."},{"key":"2026032004354109200_ref28","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/bjh.19213","article-title":"R-CHOP treatment for patients with advanced follicular lymphoma: over 15-year follow-up of JCOG0203","volume":"204","author":"Watanabe","year":"2024","journal-title":"Br J Haematol"},{"key":"2026032004354109200_ref29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"2026032004354109200_ref30","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1182\/bloodadvances.2020002567","article-title":"A randomized phase 2\/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial","volume":"5","author":"Ohmachi","year":"2021","journal-title":"Blood Adv"},{"key":"2026032004354109200_ref31","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"2026032004354109200_ref32","first-page":"CD010816","article-title":"Bortezomib for the treatment of multiple myeloma","volume":"4","author":"Scott","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032004354109200_ref33","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"2026032004354109200_ref34","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood."},{"key":"2026032004354109200_ref35","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"2026032004354109200_ref36","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026032004354109200_ref37","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/bjh.12659","article-title":"Differences in incidence and trends of haematological malignancies in Japan and the United States","volume":"164","author":"Chihara","year":"2014","journal-title":"Br J Haematol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/Supplement_1\/i103\/67423473\/hyaf145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/Supplement_1\/i103\/67423473\/hyaf145.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T08:35:50Z","timestamp":1773995750000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/Supplement_1\/i103\/8529756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":37,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2026,3,20]]},"published-print":{"date-parts":[[2026,3,20]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf145","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,3]]}}}